pomalidomide has been researched along with Lymphoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Brander, DM; Ding, W; Gui, M; He, W; Huntington, SF; Iqbal, M; Kearney, AS; Koehler, AB; Leis, JF; Mato, AR; McKinlay, TP; Moustafa, MA; Rosenthal, AC; Schuster, SJ; Tun, HW | 1 |
| Davis, DA; Jaeger, HK; Nair, A; Shrestha, P; Stream, A; Yaparla, A; Yarchoan, R | 1 |
| Atherton, PJ; DeAngelis, LM; Grommes, C; Jaeckle, KA; Johnston, PB; Koenig, PA; O'Neill, B; Omuro, AMP; Pederson, LD; Pulido, J; Reeder, CB; Schiff, D; Tun, HW; Witzig, TE | 1 |
| Babusis, D; Copland, JA; Edenfield, B; Huang, P; Katz, J; Li, Z; Moghaddam, MF; Personett, D; Qiu, Y; Shirely, MA; Tang, Y; Tun, HW | 1 |
| Brady, HA; Chan, KW; Escoubet-Lozach, L; Gandhi, AK; Jensen-Pergakes, K; Lin, IL; Muller, GW; Schafer, PH; Verhelle, D; Worland, PJ | 1 |
| Lentzsch, S; Pan, B | 1 |
1 review(s) available for pomalidomide and Lymphoma
| Article | Year |
|---|---|
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
2 trial(s) available for pomalidomide and Lymphoma
| Article | Year |
|---|---|
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dexamethasone; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retinal Neoplasms; Thalidomide; Treatment Outcome | 2018 |
3 other study(ies) available for pomalidomide and Lymphoma
| Article | Year |
|---|---|
Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas.
Topics: Cytokines; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Lymphoma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger; Up-Regulation | 2023 |
Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Central Nervous System Neoplasms; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lymphoma; Male; Mice; Mice, Nude; Rats; Thalidomide; Tumor Microenvironment; U937 Cells | 2013 |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Histone Demethylases; Histones; Humans; Lenalidomide; Lymphoma; Multiple Myeloma; Oxidoreductases, N-Demethylating; Thalidomide; Transcription Factors | 2009 |